CervoMed (CRVO) Cash & Equivalents (2022 - 2025)
CervoMed (CRVO) has disclosed Cash & Equivalents for 9 consecutive years, with $8.2 million as the latest value for Q4 2025.
- Quarterly Cash & Equivalents fell 8.49% to $8.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2025, down 8.49% year-over-year, with the annual reading at $8.2 million for FY2025, 8.49% down from the prior year.
- Cash & Equivalents hit $8.2 million in Q4 2025 for CervoMed, down from $9.4 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $15.0 million in Q2 2023 to a low of $4.1 million in Q4 2022.
- Historically, Cash & Equivalents has averaged $9.0 million across 4 years, with a median of $8.7 million in 2024.
- Biggest five-year swings in Cash & Equivalents: skyrocketed 151.43% in 2023 and later crashed 56.51% in 2024.
- Year by year, Cash & Equivalents stood at $4.1 million in 2022, then surged by 90.37% to $7.8 million in 2023, then increased by 15.48% to $9.0 million in 2024, then fell by 8.49% to $8.2 million in 2025.
- Business Quant data shows Cash & Equivalents for CRVO at $8.2 million in Q4 2025, $9.4 million in Q3 2025, and $8.3 million in Q2 2025.